MARKET

SCPH

SCPH

scPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.63
+0.09
+1.13%
Closed 16:00 07/10 EDT
OPEN
7.51
PREV CLOSE
7.55
HIGH
7.72
LOW
7.33
VOLUME
61.33K
TURNOVER
--
52 WEEK HIGH
11.99
52 WEEK LOW
3.600
MARKET CAP
204.20M
P/E (TTM)
-4.6111
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SCPH stock price target is 13.33 with a high estimate of 15.00 and a low estimate of 10.00.

EPS

SCPH News

More
scPharmaceuticals Appoints Sara Bonstein to Board of Directors
scPharmaceuticals announced the appointment of Sara Bonstein to its Board of Directors.
Business Wire · 2d ago
scPharmaceuticals Announces FUROSCIX® NDA Resubmission
Business Wire · 07/01 13:00
scPharmaceuticals Announces FUROSCIX NDA Resubmission
Benzinga · 07/01 12:24
ScPharma refiles Furoscix application in U.S.
Seeking Alpha - Article · 07/01 12:15
scPharmaceuticals (SCPH) Presents At Jefferies Virtual Healthcare Conference - Slideshow
Seeking Alpha - Article · 06/24 18:51
3 Perfect 10 Stocks Under $10 With Big Upside Potential
TipRanks · 06/23 15:50
scPharmaceuticals - An Undervalued, Under The Radar Biotech
Seeking Alpha - Article · 06/19 21:01
scPharmaceuticals Announces New Presentation Time for BMOs Virtual 2020 Prescriptions for Success Healthcare Conference
Business Wire · 06/18 13:00

Industry

Medical Equipment, Supplies & Distribution
-0.07%
Healthcare Equipment & Supplies
-0.31%

Hot Stocks

Symbol
Price
%Change

About SCPH

scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through the sc2Wear Infusor. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. The Company has completed two pivotal clinical studies, four exploratory clinical studies, and 12 human factor studies for Furoscix, and scCeftriaxone an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.
More

Webull offers kinds of Scpharmaceuticals Inc stock information, including NASDAQ:SCPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCPH stock methods without spending real money on the virtual paper trading platform.